Fig. 4

Clinical outcomes according to p-p38 MAPK, Bcl-2 expression and the DLBCL phenotype. a Event-free survival (EFS) curves for DLBCL patients treated with CHOP according to p38 MAPK and Bcl-2 expressions. b. Overall survival (OS) curves for DLBCL patients treated with CHOP according to p38 MAPK and Bcl-2 expressions. The p38 MAPK negative and Bcl-2 negative subgroups had more favorable PFS and OS than did the other two groups. c EFS curves according to the p-p38 MAPK and Bcl-2 expressions. d OS curves for DLBCL patients treated with CHOP according to p-p38 MAPK and Bcl-2 expressions. The p-p38 MAPK negative and Bcl-2 negative or positive subgroups had more favorable PFS and OS than did the other group. e EFS curves according to the p38 MAPK expression, p-p38 MAPK expression and the GC or ABC subtype. f Overall survival (OS) curve for DLBCL patients treated with CHOP according to p38 MAPK expression, p-p38 MAPK expression and the GC or ABC subtype. The p38 MAPK or p-p38 MAPK negative and GC subgroups had more favorable PFS and OS than did the other two groups